Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center prospective study of Lorlatinib for treatment of patients with ALK-rearranged NSCLC resistant to alectinib, with no prior exposure to ALK-TKIs other than alectinib and brigatinib

Next Previous
Trial Profile

A multi-center prospective study of Lorlatinib for treatment of patients with ALK-rearranged NSCLC resistant to alectinib, with no prior exposure to ALK-TKIs other than alectinib and brigatinib

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lorlatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use

Most Recent Events

  • 16 Jun 2025 New trial record
  • 30 Apr 2025 Results assessing lorlatinib's efficacy in such patients by integrating ctDNA analysis to explore predictive markers and resistance mechanisms, presented at the 116th Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top